Biotech

Cleveland BioLabs to Present at Rodman & Renshaw 17th Annual Global Investment Conference

BUFFALO, NY: ...

Novimmune and Baxalta ink international bispecific antibody collaboration

GENEVA, SWITZERLAND: ...

THC BioMed Corporate Update

VANCOUVER, BRITISH COLUMBIA: ...

Corbus Pharmaceuticals Commences Patient Enrollment in Phase 2 Clinical Study of Resunab(TM) for the Treatment of Systemic Sclerosis

NORWOOD, MA: Resunab Is a First-in-Class Drug That Induces Resolution of Inflammation; Study Will Treat Each Patient for 84 Days and Is Scheduled to Conclude in Q4 2016 ...

Sun BioPharma Announces U.S. FDA Grants IND for SBP-101 Pancreas Special Effect First in-Class Compound

MINNEAPOLIS, MN: Phase 1 Clinical Study Expected to Begin by End of Year ...

BioNeutra Global Corporation Announces Financial Results for Second Quarter Ended June 30, 2015

EDMONTON, ALBERTA: ...

Corbus Pharmaceuticals Successfully Completes Warrant Call -- Raises $11.3 mm in Total From 100% Exercise of Callable Warrants

NORWOOD, MA: Proceeds to Fund Resunab(TM) Phase 2 Studies in Cystic Fibrosis, Systemic Sclerosis and Dermatomyositis; Company Has $14.2 Million of Cash Together With $3.8 Million in Expected Milestone Payments to ...

ProMetic''s PBI-4050''s Positive Safety Review Triggers Expansion of Phase II Clinical Trial in Metabolic Syndrome Patients

LAVAL, QUEBEC: - PBI-4050 confirmed to be safe and well tolerated in the first 12 metabolic syndrome patients - Positive safety review by the Data Safety Monitoring Board ("DSMB") triggers enrollment of 24 ...

InMed Appoints Paul Brennan to the Board of Directors

VANCOUVER, BRITISH COLUMBIA: ...

BioNeutra Announces Successful Acquisition of Canadian Manufacturing Facility

EDMONTON, ALBERTA: ...